Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years

Background. The impact of recent medical advances on disease presentation, extent of operation, and disease‐specific survival for patients with medullary thyroid cancer is unclear. Methods. We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983–1992, 1993–2002, and 2003–2012. Results. There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4% in 1983–1992, 19.6% in 1993–2002, to 25.1% in 2003–2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2% to 76.5% during the study period (P < .001). In the most recent time interval, 5‐year, disease‐specific survival improved from 86% to 89% in all patients (P < .001) but especially for patients with regional (82% to 91%, P = .003) and distant (40% to 51%, P = .02) disease. Conclusion. These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease‐specific survival is also improving, primarily in patients with regional and distant disease.

[1]  M. Banerjee,et al.  The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. , 2014, The Journal of clinical endocrinology and metabolism.

[2]  X. Matías-Guiu,et al.  Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas , 1995, Cancer.

[3]  J. Moley,et al.  Medullary, anaplastic, and metastatic cancers of the thyroid. , 2010, Seminars in oncology.

[4]  Q. Duh,et al.  Medullary thyroid carcinoma , 2000, Cancer.

[5]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Roman,et al.  Medullary thyroid microcarcinoma , 2012, Cancer.

[8]  H. C. Taylor The increasing incidence of cesarean section. , 1949, Bulletin. Meriden, Conn. Hospital.

[9]  S. Roman,et al.  Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer , 2012, Clinical Medicine Insights. Oncology.

[10]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[11]  E. Kebebew,et al.  Extent of disease and practice patterns for medullary thyroid cancer. , 2005, Journal of the American College of Surgeons.

[12]  P. Fu,et al.  Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. , 2010, Surgery.

[13]  M. Schott Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial , 2012 .

[14]  A. Dackiw,et al.  Survival Implications of Cervical Lymphadenectomy in Patients with Medullary Thyroid Cancer , 2011, Annals of Surgical Oncology.

[15]  Amy Y. Chen,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  C. Key,et al.  Prognostic factors for thyroid carcinoma , 1997, Cancer.

[17]  P. Perros,et al.  2009 American Thyroid Association guidelines on thyroid nodules. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  S. Roman,et al.  Medullary Thyroid Cancer: Are Practice Patterns in the United States Discordant From American Thyroid Association Guidelines? , 2010, Annals of Surgical Oncology.

[19]  Herb Chen,et al.  The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer , 2010, Pancreas.

[20]  P. Schneider,et al.  Prognostic Value of Lymph Node Yield and Metastatic Lymph Node Ratio in Medullary Thyroid Carcinoma , 2008, Annals of Surgical Oncology.

[21]  J. Moley,et al.  Current approaches to medullary thyroid carcinoma, sporadic and familial , 2006, Journal of surgical oncology.

[22]  L. Duntas,et al.  Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[23]  T. Tosteson,et al.  The increasing incidence of thyroid cancer: the influence of access to care. , 2013, Thyroid : official journal of the American Thyroid Association.

[24]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.